Critical Illness Clinical Trial
Official title:
A Comparative Randomized Controlled Study of Arginine Free Immunoenhancing Diet and Isocaloric, Isonitrogenous Formula in Critically Ill Patients
This study intends to investigate the clinical outcomes of a new immunoenhancing formula
which composed arginine free compare to isonitrogenous, isocaloric standard formula in ICU
patients.The study design is multicenter, double-blind randomized controlled study with 3
periods of Screening, Run-in and Randomization period.
Primary Objective: To evaluate the clinical outcomes of immunoenhancing diet (IED) arginine
free in medical-surgical ICU patients.
Secondary Objective: To evaluate the immunologic effects and safety of IED arginine free
formula.
It is accepted that nutrition support is essential in the treatment of critically ill
patients. It is also reasonable to initiate nutrition support therapy as soon as possible.
Although malnutrition is most frequently associated with a risk for immune dysfunction, it
can affect all organ systems. Thus, ICU patients are in need of immunonutrients
supplementation. An additional strategy to maximize the benefits is to consider using
products supplemented with specific nutrients that modulate the immune system, improve wound
healing, and reduce oxidative stress. The lower incidence of infectious complications may
follow in shorter lengths of both intensive care units (ICU) and hospital stays. Many
studies have concentrated on nutrients to stimulate the function of cellular immunity in
these patients. These nutrients include arginine, glutamine and omega-3 fatty acid which has
direct effect on T lymphocytes and macrophage. Enteral formulas designed as immune-enhancing
diets (IED) contain supplemental amounts of L-arginine, L-glutamine, nucleotides and the
long chain polyunsaturated fatty acids: eicosapentaenoic acid (EPA), docosahexanoic acid
(DHA) and arachidonic acid (ARA) in addition to nutrient substrates essential for general
nutrition and metabolism. These formulas vary considerably in composition of these four
primary substrates. They introduce the immune cell function augmentation, inflammation
regulation and infections minimization. Glutamine, a conditional-essential amino acid, an
essential energy source, a precursor for protein synthesis and donates nitrogen for the
synthesis of purines, pyrimidines, nucleotides, amino sugars, and glutathione antioxidant.
Glutamine also plays an important role in enhancing immune cell function with no elevation
in proinflammatory cytokine production. The lower levels of glutamine have been associated
with impaired tissue healing, immune dysfunction and increased mortality.
Omega-3 fatty acid (n-3 fatty acid or omega-3 fatty acid) directly affects the function of
monocyte by membrane characteristic alteration, prostaglandin E2 (PGE2) synthesis that has
the action of macrophage phagocytosis, IL-1 and superoxide synthesis. Moreover, omega-3
fatty acid reduces cellular immune response reaction by compete arachidonic acid resulting
in less inflammation.
Arginine is considered a nutrient that enhances the immune response. Studies have shown
arginine-supplemented immune formulas in helping decrease protein catabolism, improve
nitrogen balance, enhance wound healing and wound strength resulted in less infection and
shorter hospitalization days. Arginine has also been shown to support the immune system by
enhancing lymphocyte proliferation and phagocytosis. Arginine may provide some benefits.
However, recent meta-analysis conducted in a subgroup of critically ill patients by Heyland
and colleagues revealed that arginine may be harmful to some group especially septic
patients by stimulating nitric oxide (NO) production.
Based on these scientific rationales, it is recommended that arginine should not be used in
critically ill patients who are clearly septic. And many evidences exist for supplementation
with antioxidant and immunonutrition in the critically ill. Glutamine and fish oil/borage
oil should be considered. These result in the development of immune-enhancing diet (IED)
without arginine. In addition, two types of lipids are added into the formula to further
modulate immune response. First, fish oil as a source of omega-3 fatty acids and borage oil
as a source of docosahexanoic acid (DHA), a unique omega-6 fatty acid (n-6 fatty acid). Both
n-3 and n-6 fatty acids are polyunsaturated fatty acids (PUFAs) and are essential fatty
acids (EFA). Therefore, immune-enhancing diet composes of L-glutamine, eicosapentaenoic acid
(EPA), docosahexanoic acid (DHA), antioxidant vitamins and trace minerals such as vitamin A,
vitamin E, vitamin C, selenium and betacarotene.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04551508 -
Delirium Screening 3 Methods Study
|
||
Recruiting |
NCT06037928 -
Plasma Sodium and Sodium Administration in the ICU
|
||
Completed |
NCT03671447 -
Enhanced Recovery After Intensive Care (ERIC)
|
N/A | |
Recruiting |
NCT03941002 -
Continuous Evaluation of Diaphragm Function
|
N/A | |
Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
Completed |
NCT04239209 -
Effect of Intensivist Communication on Surrogate Prognosis Interpretation
|
N/A | |
Completed |
NCT05531305 -
Longitudinal Changes in Muscle Mass After Intensive Care
|
N/A | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Completed |
NCT02916004 -
The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients.
|
N/A | |
Recruiting |
NCT05883137 -
High-flow Nasal Oxygenation for Apnoeic Oxygenation During Intubation of the Critically Ill
|
||
Completed |
NCT04479254 -
The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study)
|
N/A | |
Recruiting |
NCT04475666 -
Replacing Protein Via Enteral Nutrition in Critically Ill Patients
|
N/A | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Not yet recruiting |
NCT04538469 -
Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
|
||
Withdrawn |
NCT04043091 -
Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction
|
N/A | |
Recruiting |
NCT02989051 -
Fluid Restriction Keeps Children Dry
|
Phase 2/Phase 3 | |
Recruiting |
NCT02922998 -
CD64 and Antibiotics in Human Sepsis
|
N/A | |
Completed |
NCT02899208 -
Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients?
|
N/A | |
Completed |
NCT03048487 -
Protein Consumption in Critically Ill Patients
|
||
Recruiting |
NCT02163109 -
Oxygen Consumption in Critical Illness
|